Alterations of fecal bacterial communities in patients with lung cancer

American Journal of Translational Research

Volumn 10, Issue 10, 2018, Pages 3171-3185

  Zhang, Wei Quan ^a,b   Zhao, Shu Kang ^a,b   Luo, Jun Wen ^a,b   Dong, Xiao Peng ^a   Hao, Ying Tao ^a   Li, Hui ^a   Shan, Lei ^a   Zhou, Yong ^a   Shi, Hu Bo ^c   Zhang, Zai Yun ^a   Peng, Chuan Liang ^a   Zhao, Xiao Gang ^a  

^a THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c SHANDONG PROVINCIAL CHEST HOSPITAL   (China)

Author keywords

16S rRNA gene sequencing; Carcinogenesis; Gut bacteria; Lung cancer; Microbial dysbiosis

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 6; RNA 16S;

ADULT; ARTICLE; BACTERIAL GENE; BACTERIUM DETECTION; BIOINFORMATICS; CONTROLLED STUDY; DIALISTER; DNA EXTRACTION; DYSBIOSIS; ENTEROBACTER; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA; FECES ANALYSIS; FECES MICROFLORA; FEMALE; FIRMICUTES; FUSOBACTERIUM; HUMAN; INTESTINE FLORA; KLUYVERA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MICROBIAL COMMUNITY; MICROBIAL DIVERSITY; MIDDLE AGED; NEUTROPHIL LYMPHOCYTE RATIO; PLATELET LYMPHOCYTE RATIO; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; RNA SEQUENCE; SHIGELLA; VEILLONELLA;

EID: 85056165391     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Kamangar F, Dores GM and Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-2150.
2. Hong QY, Wu GM, Qian GS, Hu CP, Zhou JY, Chen LA, Li WM, Li SY, Wang K, Wang Q, Zhang XJ, Li J, Gong X, Bai CX; Lung Cancer Group of Chinese Thoracic Society; Chinese Alliance Against Lung Cancer. Prevention and management of lung cancer in China. Cancer 2015; 121 Suppl 17: 3080-3088.
3. Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, Kunkler I; EUROCARE-4 Working Group. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 2007; 8: 784-796.
4. Zheng R, Zeng H, Zuo T, Zhang S, Qiao Y, Zhou Q and Chen W. Lung cancer incidence and mortality in China, 2011. Thorac Cancer 2016; 7: 94-99.
5. Alexandrov LB, Ju YS, Haase K, Van Loo P, Martincorena I, Nik-Zainal S, Totoki Y, Fujimoto A, Nakagawa H, Shibata T, Campbell PJ, Vineis P, Phillips DH and Stratton MR. Mutational signatures associated with tobacco smoking in human cancer. Science 2016; 354: 618-622.
6. Bozinovski S, Vlahos R, Anthony D, McQualter J, Anderson G, Irving L and Steinfort D. COPD and squamous cell lung cancer: aberrant inflammation and immunity is the common link. Br J Pharmacol 2016; 173: 635-648.
7. Garrett WS. Cancer and the microbiota. Science 2015; 348: 80-86.
8. Ley RE, Peterson DA and Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 2006; 124: 837-848.
9. Schwabe RF and Jobin C. The microbiome and cancer. Nat Rev Cancer 2013; 13: 800-812.
10. Mao Q, Jiang F, Yin R, Wang J, Xia W, Dong G, Ma W, Yang Y, Xu L and Hu J. Interplay between the lung microbiome and lung cancer. Cancer Lett 2017; 415: 40-48.
11. Dapito DH, Mencin A, Gwak GY, Pradere JP, Jang MK, Mederacke I, Caviglia JM, Khiabanian H, Adeyemi A, Bataller R, Lefkowitch JH, Bower M, Friedman R, Sartor RB, Rabadan R and Schwabe RF. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012; 21: 504-516.
12. Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillere R, Hannani D, Enot DP, Pfirschke C, Engblom C, Pittet MJ, Schlitzer A, Ginhoux F, Apetoh L, Chachaty E, Woerther PL, Eberl G, Berard M, Ecobichon C, Clermont D, Bizet C, GaboriauRouthiau V, Cerf-Bensussan N, Opolon P, Yessaad N, Vivier E, Ryffel B, Elson CO, Dore J, Kroemer G, Lepage P, Boneca IG, Ghiringhelli F and Zitvogel L. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013; 342: 971-976.
13. Cameron SJ, Lewis KE, Huws SA, Hegarty MJ, Lewis PD, Pachebat JA and Mur LA. A pilot study using metagenomic sequencing of the sputum microbiome suggests potential bacterial biomarkers for lung cancer. PLoS One 2017; 12: e0177062.
14. Lee SH, Sung JY, Yong D, Chun J, Kim SY, Song JH, Chung KS, Kim EY, Jung JY, Kang YA, Kim YS, Kim SK, Chang J and Park MS. Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions. Lung Cancer 2016; 102: 89-95.
15. Yu G, Gail MH, Consonni D, Carugno M, Humphrys M, Pesatori AC, Caporaso NE, Goedert JJ, Ravel J and Landi MT. Characterizing human lung tissue microbiota and its relationship to epidemiological and clinical features. Genome Biology 2016; 17: 163.
16. Zhang L, Xiao H, Zhou H, Santiago S, Lee JM, Garon EB, Yang J, Brinkmann O, Yan X, Akin D, Chia D, Elashoff D, Park NH and Wong DT. Development of transcriptomic biomarker signature in human saliva to detect lung cancer. Cell Mol Life Sci 2012; 69: 3341-3350.
17. Michaud DS, Liu Y, Meyer M, Giovannucci E and Joshipura K. Periodontal disease, tooth loss, and cancer risk in male health professionals: a prospective cohort study. Lancet Oncol 2008; 9: 550-558.
18. Yan X, Yang M, Liu J, Gao R, Hu J, Li J, Zhang L, Shi Y, Guo H, Cheng J, Razi M, Pang S, Yu X and Hu S. Discovery and validation of potential bacterial biomarkers for lung cancer. Am J Cancer Res 2015; 5: 3111-3122.
19. Gui QF, Lu HF, Zhang CX, Xu ZR and Yang YH. Well-balanced commensal microbiota contributes to anti-cancer response in a lung cancer mouse model. Genet Mol Res 2015; 14: 5642-5651.
20. Geller LT, Barzily-Rokni M, Danino T, Jonas OH, Shental N, Nejman D, Gavert N, Zwang Y, Cooper ZA, Shee K, Thaiss CA, Reuben A, Livny J, Avraham R, Frederick DT, Ligorio M, Chatman K, Johnston SE, Mosher CM, Brandis A, Fuks G, Gurbatri C, Gopalakrishnan V, Kim M, Hurd MW, Katz M, Fleming J, Maitra A, Smith DA, Skalak M, Bu J, Michaud M, Trauger SA, Barshack I, Golan T, Sandbank J, Flaherty KT, Mandinova A, Garrett WS, Thayer SP, Ferrone CR, Huttenhower C, Bhatia SN, Gevers D, Wargo JA, Golub TR and Straussman R. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science 2017; 357: 1156-1160.
21. Yu T, Guo F, Yu Y, Sun T, Ma D, Han J, Qian Y, Kryczek I, Sun D, Nagarsheth N, Chen Y, Chen H, Hong J, Zou W and Fang JY. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell 2017; 170: 548-563.
22. Routy B, Le Chatelier E, Derosa L, Duong CP, Alou MT, Daillere R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragon L, Jacquelot N, Qu B, Ferrere G, Clemenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G and Zitvogel L. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 2018; 359: 91-97.
23. Sze MA, Tsuruta M, Yang SW, Oh Y, Man SF, Hogg JC and Sin DD. Changes in the bacterial microbiota in gut, blood, and lungs following acute LPS instillation into mice lungs. PLoS One 2014; 9: e111228.
24. Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, Molina DA, Salcedo R, Back T, Cramer S, Dai RM, Kiu H, Cardone M, Naik S, Patri AK, Wang E, Marincola FM, Frank KM, Belkaid Y, Trinchieri G and Goldszmid RS. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013; 342: 967-970.
25. Abreu MT and Peek RM Jr. Gastrointestinal malignancy and the microbiome. Gastroenterology 2014; 146: 1534-1546.
26. Maroof H, Hassan ZM, Mobarez AM and Mohamadabadi MA. Lactobacillus acidophilus could modulate the immune response against breast cancer in murine model. J Clin Immunol 2012; 32: 1353-1359.
27. He Y, Wen Q, Yao F, Xu D, Huang Y and Wang J. Gut-lung axis: the microbial contributions and clinical implications. Crit Rev Microbiol 2017; 43: 81-95.
28. Fan X, Alekseyenko AV, Wu J, Peters BA, Jacobs EJ, Gapstur SM, Purdue MP, Abnet CC, Stolzenberg-Solomon R, Miller G, Ravel J, Hayes RB and Ahn J. Human oral microbiome and prospective risk for pancreatic cancer: a populapopula tion-based nested case-control study. Gut 2018; 67: 120-127. tion-based
29. Magoc T and Salzberg SL. FLASH: fast length adjustment of short reads to improve genome assemblies. Bioinformatics 2011; 27: 2957-2963.
30. Bokulich NA, Subramanian S, Faith JJ, Gevers D, Gordon JI, Knight R, Mills DA and Caporaso JG. Quality-filtering vastly improves diversity estimates from Illumina amplicon sequencing. Nat Methods 2013; 10: 57-59.
31. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Pena AG, Goodrich JK, Gordon JI, Huttley GA, Kelley ST, Knights D, Koenig JE, Ley RE, Lozupone CA, McDonald D, Muegge BD, Pirrung M, Reeder J, Sevinsky JR, Turnbaugh PJ, Walters WA, Widmann J, Yatsunenko T, Zaneveld J and Knight R. QIIME allows analysis of highthroughput community sequencing data. Nat Methods 2010; 7: 335-336.
32. Edgar RC, Haas BJ, Clemente JC, Quince C and Knight R. UCHIME improves sensitivity and speed of chimera detection. Bioinformatics 2011; 27: 2194-2200.
33. Haas BJ, Gevers D, Earl AM, Feldgarden M, Ward DV, Giannoukos G, Ciulla D, Tabbaa D, Highlander SK, Sodergren E, Methe B, DeSantis TZ, Human Microbiome C, Petrosino JF, Knight R and Birren BW. Chimeric 16S rRNA sequence formation and detection in Sanger and 454-pyrosequenced PCR amplicons. Genome Res 2011; 21: 494-504.
34. Edgar RC. UPARSE: highly accurate OTU sequences from microbial amplicon reads. Nat Methods 2013; 10: 996-998.
35. DeSantis TZ, Hugenholtz P, Larsen N, Rojas M, Brodie EL, Keller K, Huber T, Dalevi D, Hu P and Andersen GL. Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl Environ Microbiol 2006; 72: 5069-5072.
36. Wang Q, Garrity GM, Tiedje JM and Cole JR. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol 2007; 73: 5261-5267.
37. White JR, Nagarajan N and Pop M. Statistical methods for detecting differentially abundant features in clinical metagenomic samples. PLoS Comput Biol 2009; 5: e1000352.
38. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS and Huttenhower C. Metagenomic biomarker discovery and explanation. Genome Biol 2011; 12: R60.
39. Coleman OI and Nunes T. Role of the microbiota in colorectal cancer: updates on microbial associations and therapeutic implications. Biores Open Access 2016; 5: 279-288.
40. Xuan C, Shamonki JM, Chung A, Dinome ML, Chung M, Sieling PA and Lee DJ. Microbial dysbiosis is associated with human breast cancer. PLoS One 2014; 9: e83744.
41. Marsh RL, Kaestli M, Chang AB, Binks MJ, Pope CE, Hoffman LR and Smith-Vaughan HC. The microbiota in bronchoalveolar lavage from young children with chronic lung disease includes taxa present in both the oropharynx and nasopharynx. Microbiome 2016; 4: 37.
42. Liu HX, Tao LL, Zhang J, Zhu YG, Zheng Y, Liu D, Zhou M, Ke H, Shi MM and Qu JM. Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects. Int J Cancer 2018; 142: 769-778.
43. Hosgood HD 3rd, Sapkota AR, Rothman N, Rohan T, Hu W, Xu J, Vermeulen R, He X, White JR, Wu G, Wei F, Mongodin EF and Lan Q. The potential role of lung microbiota in lung cancer attributed to household coal burning exposures. Environ Mol Mutagen 2014; 55: 643-651.
44. Nowak P, Troseid M, Avershina E, Barqasho B, Neogi U, Holm K, Hov JR, Noyan K, Vesterbacka J, Svard J, Rudi K and Sonnerborg A. Gut microbiota diversity predicts immune status in HIV-1 infection. AIDS 2015; 29: 2409-2418.
45. Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK and Knight R. Diversity, stability and resilience of the human gut microbiota. Nature 2012; 489: 220-230.
46. Li Y, Liu T, Yan C, Xie R, Guo Z, Wang S, Zhang Y, Li Z, Wang B and Cao H. Diammonium glycyrrhizinate protects against non-alcoholic fatty liver disease in mice through modulation of gut microbiota and restoring intestinal barrier. Mol Pharm 2018.
47. Etxeberria U, Arias N, Boque N, Macarulla MT, Portillo MP, Martinez JA and Milagro FI. Reshaping faecal gut microbiota composition by the intake of trans-resveratrol and quercetin in high-fat sucrose diet-fed rats. J Nutr Biochem 2015; 26: 651-660.
48. Meijer K, de Vos P and Priebe MG. Butyrate and other short-chain fatty acids as modulators of immunity: what relevance for health? Curr Opin Clin Nutr Metab Care 2010; 13: 715-721.
49. Verdam FJ, Fuentes S, de Jonge C, Zoetendal EG, Erbil R, Greve JW, Buurman WA, de Vos WM and Rensen SS. Human intestinal microbiota composition is associated with local and systemic inflammation in obesity. Obesity (Silver Spring) 2013; 21: E607-615.
50. Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, Nakanishi Y, Uetake C, Kato K, Kato T, Takahashi M, Fukuda NN, Murakami S, Miyauchi E, Hino S, Atarashi K, Onawa S, Fujimura Y, Lockett T, Clarke JM, Topping DL, Tomita M, Hori S, Ohara O, Morita T, Koseki H, Kikuchi J, Honda K, Hase K and Ohno H. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013; 504: 446-450.
51. Inan MS, Rasoulpour RJ, Yin L, Hubbard AK, Rosenberg DW and Giardina C. The luminal short-chain fatty acid butyrate modulates NFkappaB activity in a human colonic epithelial cell line. Gastroenterology 2000; 118: 724-734.
52. Gao Z, Guo B, Gao R, Zhu Q and Qin H. Microbiota disbiosis is associated with colorectal cancer. Front Microbiol 2015; 6: 20.
53. Shin NR, Whon TW and Bae JW. Proteobacteria: microbial signature of dysbiosis in gut microbiota. Trends Biotechnol 2015; 33: 496-503.
54. Gholizadeh P, Eslami H and Kafil HS. Carcinogenesis mechanisms of Fusobacterium nucleatum. Biomed Pharmacother 2017; 89: 918-925.
55. Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, Ojesina AI, Jung J, Bass AJ, Tabernero J, Baselga J, Liu C, Shivdasani RA, Ogino S, Birren BW, Huttenhower C, Garrett WS and Meyerson M. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 2012; 22: 292-298.
56. Castellarin M, Warren RL, Freeman JD, Dreolini L, Krzywinski M, Strauss J, Barnes R, Watson P, Allen-Vercoe E, Moore RA and Holt RA. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 2012; 22: 299-306.
57. Erb-Downward JR, Thompson DL, Han MK, Freeman CM, McCloskey L, Schmidt LA, Young VB, Toews GB, Curtis JL, Sundaram B, Martinez FJ and Huffnagle GB. Analysis of the lung microbiome in the “healthy” smoker and in COPD. PLoS One 2011; 6: e16384.
58. Frankel AE, Coughlin LA, Kim J, Froehlich TW, Xie Y, Frenkel EP and Koh AY. Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients. Neoplasia 2017; 19: 848-855.
59. Sharpton T, Lyalina S, Luong J, Pham J, Deal EM, Armour C, Gaulke C, Sanjabi S and Pollard KS. Development of inflammatory bowel disease is linked to a longitudinal restructuring of the gut metagenome in mice. mSystems 2017; 2.
60. Hergott CB, Roche AM, Tamashiro E, Clarke TB, Bailey AG, Laughlin A, Bushman FD and Weiser JN. Peptidoglycan from the gut microbiota governs the lifespan of circulating phagocytes at homeostasis. Blood 2016; 127: 2460-2471.
61. Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O’Reilly DS, Foulis AK, Horgan PG and McMillan DC. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 2011; 47: 2633-2641.
62. Paramanathan A, Saxena A and Morris DL. A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours. Surg Oncol 2014; 23: 31-39.
63. Fiala O, Sorejs O, Pesek M and Finek J. [Immunotherapy in the treatment of lung cancer]. Klin Onkol 2017; 30: 22-31.